Navigation Links
Pharmatech Oncology Receives Phase 2 SBIR Funding for Just-In-Time Enrollment Model
Date:8/9/2012

DENVER, Aug. 9, 2012 /PRNewswire/ -- Pharmatech Oncology announces the award of its phase 2 Small Business Innovative Research (SBIR) project, entitled A Patient Centered Approach to Enrolling Rare Cancer Patients in Clinical Trials, to be funded through the National Cancer Institute (NCI).

Pharmatech Oncology has developed an innovative enrollment methodology called Just-In-Time (JIT) to improve enrollment rates into cancer clinical trials, which often see significant delays due to slow patient enrollment.  The major challenge in developing more effective anti-cancer drugs is the time it takes to complete clinical trials demonstrating the safety and efficacy of investigational new drugs. With only an estimated 3 to 5 percent of adult cancer patients participating in clinical trials, and potentially even fewer being offered the opportunity, JIT provides patients with on-demand access to cancer clinical trials and investigational treatments.

In Phase 1 of the SBIR project, Pharmatech Oncology demonstrated that cancer trial enrollment rates can be increased by making specific clinical trials available to a network of research ready centers (Click this link to see the abstract: http://intl-dij.sagepub.com/content/46/4/472.abstract). The JIT enrollment model puts patients first in the research process, prioritizing selection of the most appropriate therapy, and utilizing highly efficient workflow to enroll individual cancer patients into a trial in 10 days or less.

The Phase 2 project addresses the scalability of the JIT enrollment methodology as an industry-wide solution, but even more exciting is its focus on aligning patient genetic and molecular characteristics with personalized therapy. The principal investigator of the project, Dr. Matthew Wiener, believes, "The JIT enrollment methodology is ideally positioned to support the development of targeted cancer medicine by helping oncologists to select the right drugs for the right patients at the right time.

"With the continued support of the NCI through the SBIR program, Pharmatech Oncology is now positioned to advance this innovative approach in partnership with the other stakeholders in cancer research: the trial sponsors, research and advocacy organizations, the hematology-oncology professional community, and most of all cancer patients," said Dr. Wiener. "We want every cancer patient to have the best treatment options, including these advanced clinical trials."

About Pharmatech Oncology, Inc.:

Pharmatech Oncology, headquartered in Denver, Colorado, is a Contract Research Organization (CRO) that specializes in creating efficiency in cancer clinical trials. We provide a patient centered approach for the investigational treatment of cancer by organizing and directing the entire research process, from start to finish.

For more information about Pharmatech, please visit www.pharmatechoncology.com.

The project described is supported by Award Number R44CA144362 from the National Cancer institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.


'/>"/>
SOURCE Pharmatech Oncology, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. WuXi PharmaTech Announces First-Quarter 2012 Results
2. Industry Leading Pharmaceutical News Website in-Pharmatechnologist.com Refocused and Relaunched
3. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
4. Champions Oncology Reports Resignation Of Director
5. Center for Medicare & Medicaid Innovation Awards $19 Million Grant to Develop Oncology Medical Home Model
6. Pharmaceutical Pricing and Reimbursement in Oncology - Payer Pressure to Justify Premium Pricing of Novel Agents, Pushing Companies to Risk-Sharing Modalities
7. Radiation Therapy in Oncology Drug Pipeline Update 2012
8. Medical Oncology Association of Southern California Purchasing Network (MPN) Names Cardinal Health Specialty Solutions as its Primary Healthcare Solutions Partner
9. Schulman Associates IRB offers oncology-focused review board
10. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
11. Velos, Inc. Introduces Mobile App for Oncology Adverse Events and Graft-Versus-Host Disease at 2012 ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... LAUDERDALE, Fla. , July 25, 2017  Debbie,s Dream Foundation: Curing Stomach ... Luncheon on Monday, September 25, 2017 at the Bonaventure Resort & Spa in ... ... Gendler, DDF Founder and President Debbie Zelman, and Luncheon Committee Co-chair Sabrina Kurzman. ... ...
(Date:7/21/2017)... , July 21, 2017  Endo International plc (NASDAQ: ... a comprehensive review of its manufacturing network, the Company ... distribution facilities in Huntsville, Alabama . ... place over the next 12 to 18 months. The ... by declining volumes of commoditized products and these restructuring ...
(Date:7/15/2017)... 2017 Enterin Inc., a Philadelphia ... (PD), today announced the completion of a $12.7 million Series ... III, as well as the participation of existing investors. ... have the support of New Ventures III and our current ... of the potential of our platform technology to transform the ...
Breaking Medicine Technology:
(Date:7/27/2017)... TX (PRWEB) , ... July 27, 2017 , ... ... receive a new set of teeth in a single office visit from Dr. ... and comfortable treatment solutions to his East Texas patients, including Teeth-in-a-Day® dental ...
(Date:7/27/2017)... ... July 27, 2017 , ... Somnoware, a leading ... (PSG) distributed scoring solution to its healthcare management platform. This solution provides physicians ... speed and functionality of scoring in the cloud is on par with doing ...
(Date:7/27/2017)... California (PRWEB) , ... July 27, 2017 , ... The Los Angeles leg of the ... 3rd, 2017 at 7:00pm and will be held at the Clive Davis Theater inside the ... the Camo Jacket, chronicles the story of the iconic Welsh rock musician, Mike Peters (of ...
(Date:7/27/2017)... ... 2017 , ... Team Novo Nordisk, the world’s first all-diabetes professional cycling team, ... a stagiaire for the remainder of the 2017 season. One of our best development ... Tour of Utah. , “Every season we are excited to move an athlete from ...
(Date:7/26/2017)... ... July 26, 2017 , ... Capillus, LLC has announced the redesign ... The new Flexible Fitting Design offers a more comfortable, adaptable fit and is available ... the improvements to the home-use laser therapy caps intended to improve both user experience ...
Breaking Medicine News(10 mins):